EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.6400
-0.0510 (-3.02%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.6910
Open1.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.6268 - 1.7100
52 Week Range1.4800 - 4.5000
Volume194,824
Avg. Volume229,960
Market Cap234.654M
Beta (3Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.1290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 7 Marijuana Stocks With Critical Levels to Watch
    InvestorPlace2 days ago

    7 Marijuana Stocks With Critical Levels to Watch

    [Editor's note: This story will be updated each week with new stocks and analysis. Please check back often for Mark's latest take on marijuana stocks.]Yesterday I heard an investor say that technical analysis is like reading tea leaves. I am not surprised by this because most technical analysts do not seem to understand just what it is that they are supposed to be doing.These analysts look at charts and mindlessly identify patterns without understanding what they are supposed to mean. Some even promote esoteric methods like Gann Theory and Elliot waves that institutional traders do not use.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn financial markets, some levels are more important than others. In addition, prices are always doing one of three things. They are going up, going down, or staying the same. If understood and used correctly, technical analysis should illustrate these levels and trends.Understanding these dynamics can help you profit. Short-term traders need to know which levels are important in order to be successful. Long-term investors can benefit by having a better understanding of where to place their buy and sell orders.For example, suppose that you buy a stock at $20. The market starts to go your way and you plan sell it when it gets to $30. A look at a chart may show that there is significant resistance at the $29 level. This means that your stock may never get to $30. It may rally and hit the resistance at $29 and then sell off and drop back to $20. If you were waiting for $30, you would have missed out on making a significant profit. * 7 Stocks Top Investors Are Buying Now Here are some interesting dynamics that are playing out in seven marijuana stocks. Technical Levels in Marijuana Stocks: Trulieve Cannabis (TCNNF)Trulieve Cannabis (OTCMKTS:TCNNF) develops medical cannabis products. The classic head & shoulders pattern continues to play out in TCNNF.Like most things in technical analysis, this pattern is widely misunderstood. Most of the alleged H&S patterns that I see in the financial media are not actually H&S patterns.First of all, the head and shoulders pattern is a reversal pattern. That means it needs to come at the end of a meaningful trend. There is no such thing as a head and shoulders continuation pattern, at least by a classic definition. The left shoulder here formed after a 50% move in two months. That is clearly a meaningful trend.Second, the volume needs to support the pattern. Most volume has to be in the left shoulder or head. This increasing volume means the smart money is selling their positions to the buyers that are late to the rally.Once we get to the right shoulder, the volume drops. This is because most buyers have completed their orders. Since there is not sufficient buy interest anymore, the stock price will eventually drop.The traditional way to determine a price target with a head-and-shoulders pattern is to take the distance from head to the neckline and subtract it from the neckline. In this case, that would suggest TCNNF will continue to decline. Cronos (CRON)Cronos (NASDAQ:CRON) grows and sell marijuana.Last week I discussed the importance of the $14 level to CRON stock. It has been a support level since May. On July 12 and July 15, that is almost exactly where the low trades were. Had you bought it, you would be looking at a nice profit as it is now trading above $15.The reason why the $14 level is support is because it was a resistance level during last September and December.How does a level that was resistance become a support level?There are two types of sellers. There are short-sellers and there are sellers who are selling stock that they hold. The people who sold at $14 were feeling pretty good after the stock went down. The short-sellers were looking at a profit and the long sellers think they made the right decision.Then the stock rallies above $14. Now the short-sellers are losing money and tell themselves that if it comes back to $14, they will by it back. Those who sold their shares now think that they made a mistake and tell themselves if they can, they will buy it again at $14. * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip Meanwhile, those who bought it at $14 wish they bought more. They tell themselves if it comes back to $14, they will add to their positions. Added to this are professional traders who see a clear level to trade off of.The buy interest of these four groups at $14 creates the support level. Canopy Growth (CGC)Canopy Growth (NYSE:CGC) grows and sells marijuana.The gap that I spoke about last week in CGC stock is refilling. The action here shows how what gaps up may gap down, and vice-versa.When a stock makes a big move in a short period of time, traders say "it gapped up" or "it gapped down". You can see that Canopy Growth stock gapped up in early January when it rallied from $30 to $40 in just a few days.Now that you know how support levels form, it is easy to understand why gaps refill. Those who sold a stock at a particular level buy it back if the stock rallies and then retreats to that level.When a stock gaps, it does not spend much time trading at the levels it gaps through. Because of this, there isn't enough time for buy interest to be created, so meaningful support does not form. This is why when a stock gaps up through a range, it may later gap down through it. That is what we have seen with CGC stock. Emerald Health Therapeutics (EMHTF)Emerald Health Therapeutics (OTCMKTS:EMHTF) is a pharmaceutical company that makes cannabis products.EMHTF is testing support at the $1.75 level. This level was also support in December. If you like the long-term prospects of the company, this is probably a good time to buy it.There is a story here that may be a very bullish dynamic for this company. Emerald Health just announced that it has received its cultivation license from the Canadian government for a large outdoor cultivation area.Investors are starting to realize that growing outside is substantially cheaper than indoor or greenhouse growing. There are advantages to these more expensive methods, such as enhanced security and better quality, but the cost advantages of outdoor growing more than offsets them. * 7 Dependable Dividend Stocks to Buy This move into outdoor growing may show that the company is positioning itself for the future. Curaleaf Holdings (CURLF)Curaleaf Holdings (OTCMKTS:CURLF) is a life sciences company that owns and manages licensed cannabis businesses. And CURLF stock shows us the concept of a trend.There is considerable confusion around trends and trendlines. In fact, I recently saw one well-known technical analyst say that trendlines are not valid. I have no idea what he is talking about.In financial markets, prices are either going up, down, or staying the same. When they are going down the forces of supply are in control. When they are rising the forces of demand are in control. When prices are not changing the forces are equal.If properly used and understood correctly, trendlines should simply be a graphical illustration of these dynamics. Of course, it takes some practice and experience but they are not "mathematical absurdities."Here we see that the forces of supply controlled the CURLF market from May until this week, when the downtrend line was broken. This simply means that the forces of supply may be taking over, or at least equalizing with the forces of demand. Aphria (APHA)Aphria (NYSE:APHA) grows and sells cannabis, and APHA stock continues to trade between resistance at the $7.30 level and support around the $6.25 level. It looked like it was going to break recently, but then the stock became oversold and rebounded.If the support at $6.25 breaks, it will probably become a resistance level. This happens just as explained in the Canopy section, except going in the opposite direction. * The 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond As multiple groups of sellers converge on one area in the chart, resistance forms. CURE Pharmaceutical Holding Corp (CURR)CURE Pharmaceutical Holding Corp (OTCMKTS:CURR) develops and manufactures drugs and drug delivery systems.The action here once again shows how a resistance level becomes a support level. We identified this level last week. If you bought it you would be up over 10%.I find support and resistance level to be amazing things. Few people appreciate them. Academics say they shouldn't exist but clearly, they do.Resistance and support levels are really illustrations of mass psychology. Some exchange-traded funds or stocks have literally millions of share holders. Each one of these holders has their own agenda, yet somehow their combined actions create clear levels in the markets.Even after studying the markets for over 20 years I still can't fully comprehend how or why this happens. It reminds me of how ant colonies move to find new nests. Every individual ant just does its own thing, yet somehow the combined actions of millions of ants moves the colony.Now there is something to think about the next time you use some of these companies' products.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks Top Investors Are Buying Now * The 10 Best Cryptocurrencies to Keep on Your Radar * 7 Marijuana Penny Stocks That Could Triple (But You Won't Make Money) The post 7 Marijuana Stocks With Critical Levels to Watch appeared first on InvestorPlace.

  • GlobeNewswire5 days ago

    Emerald Health Therapeutics’ New Organic Cannabis Operation Receives Cultivation License for Outdoor Grow Area

    OTCQX: EMHTF) has received its cultivation license from Health Canada for the 12-acre outdoor grow area at its new organic cannabis operation in Metro Vancouver, BC. The outdoor grow area is expected to be capable of producing approximately 10,000 kg of cannabis annually with multiple crops during a full growing season. With this license effective as of July 12, 2019, Emerald is positioned to deliver one harvest and a portion of the expected full production volume this year. The 12 acres (~500,000 square feet) of outdoor cultivation are part of an overall 20-acre site that includes 156,000 sq. ft. in two greenhouses.

  • GlobeNewswire9 days ago

    Emerald Health Therapeutics’ Joint Venture Achieves Its Full Annualized Production Run-Rate

    OTCQX: EMHTF) 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has achieved its full production run-rate of 75,000 kilograms of dried cannabis at its 1.1 million square foot Delta 3 greenhouse in Delta, British Columbia. “Pure Sunfarms’ growing operation is setting the standard for large-scale low cost high quality cannabis production, which we believe serves as a strong indication of what the combined expertise of Emerald and Village Farms can accomplish,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.

  • GlobeNewswire10 days ago

    Emerald Health Therapeutics Expands Distribution of its SYNC 25 CBD Oil to Two More Canadian Provinces

    VANCOUVER, British Columbia, July 10, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 9,960 40-ml units of its SYNC 25 CBD oil to.

  • GlobeNewswire17 days ago

    Emerald Health Therapeutics Commends Government of Ontario for Expanding Retail Cannabis Store Licences in Canada’s Largest Province

    OTCQX: EMHTF) commends the Government of Ontario for its newly announced plans to expand the province’s brick-and-mortar retail sales network for adult-use cannabis. Emerald believes that this initiative will position the industry and the Company for significant sales growth in Canada’s largest province. “After the first 25 stores began to open in Ontario, the industry saw overall sales of cannabis basically double,” said Dr. Avtar Dhillon, Executive Chairman and President of Emerald.

  • GlobeNewswire18 days ago

    Emerald Health Therapeutics Joint Venture Launches Cannabis-Free Endocannabinoid-Supporting Health Supplement in Canada

    OTCQX: EMHTF), through its joint venture Emerald Health Naturals (“EHN”), has introduced a cannabis-free herbal and botanical endocannabinoid-supporting health supplement product line in Canada. EHN’s Endo products, which do not contain cannabis or its derivatives, aim to support the endocannabinoid system to help maintain equilibrium in the body and are already available in over 200 natural health food stores across Canada.

  • GlobeNewswire26 days ago

    Emerald Health Therapeutics Receives Cultivation License for New-Build Organic Cannabis Operation in British Columbia

    OTCQX: EMHTF) has received its initial cultivation license from Health Canada for its new organic cannabis growing facility in Metro Vancouver, BC. Tailor-made for Emerald to produce high-quality organic cannabis, the operation comprises two 78,000 square foot greenhouses and 12 acres (~500,000 square feet) of outdoor cultivation, with potential for an additional 12 acres.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Applauds the Government of Canada for the Release of Final Ingestible Regulations

    OTCQX: EMHTF) is pleased that today the Government of Canada released the final regulatory framework for ingestibles and edibles. “The clarity of the final regulatory framework provides is important for Emerald in bringing our new product categories such as vape pens, ingestibles and edibles to market,” said Allan Rewak, VP Communications and Stakeholder Relations. The regulatory framework announced by Health Canada prohibits product forms that could be appealing to children and youth, combine alcohol or nicotine with cannabis and restrict production of infused cannabis products to dedicated licenced cannabis facilities approved by Health Canada.

  • GlobeNewswirelast month

    Emerald Health Therapeutics to Present At Oppenheimer Consumer Growth and E-Commerce Conference

    OTCQX: EMHTF), a licensed producer of cannabis products for medical and recreational purposes, will participate in the Oppenheimer 19th Annual Consumer Growth and E-Commerce Conference on June 18, 2019 in Boston, MA. Bernie Hertel, Vice President of Finance and Communications, Emerald Health Sciences, will present a corporate overview and be available for 1x1 meetings.

  • GlobeNewswirelast month

    Emerald Health Therapeutics Contracts for 1,200 Acres of Canadian Hemp Harvest, Reports Significant Progress on Factors Group Extraction Facility, and Forms US Hemp Subsidiary

    OTCQX: EMHTF) reports that is has expanded its agreement to purchase harvested hemp flower and leaf, or hemp chaff, from Emerald Health Hemp Inc. (“EHH”) from 1,000 to 1,200 acres for 2019. EHH is a wholly owned subsidiary of Emerald Health Sciences Inc. and a related party of Emerald. Based on last year’s harvest, Emerald expects production from the 1,200 acres to be at least 270,000 kg of hemp chaff in 2019 with, conservatively, approximately 2% cannabidiol (“CBD”) content.

  • OTC Markets Group Launches OTCQX Cannabis Index
    PR Newswire2 months ago

    OTC Markets Group Launches OTCQX Cannabis Index

    NEW YORK , June 4, 2019 /PRNewswire/ --  OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the launch of the OTCQX® Cannabis Index ...

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics to Participate at Investment and Industry Conferences in June

    VANCOUVER, British Columbia, June 03, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in multiple upcoming investment and.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Reports First Quarter 2019 Financial Results; Demonstrates Continued Growth in Sales

    VANCOUVER, British Columbia, May 31, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended.

  • ACCESSWIRE2 months ago

    Emerald Health Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 31, 2019 / Emerald Health Therapeutics, Inc. (TSXVENTURE: EMHTF ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 31, 2019 ...

  • GlobeNewswire2 months ago

    Emerald Completes Issuance of Shares in Lieu of Cash Due for Verdélite Acquisition

    OTCQX: EMHTF) today announced that the vendors (the "Vendors") of Verdélite Sciences, Inc. and Verdélite Property Holdings, Inc. (collectively, "Verdélite") have received 2,129,707 shares of Emerald (the "Shares") in lieu of $7.5 million of the $22.5 million they were to receive as the final payment for their shares of Verdélite. Each Share was valued at $3.5216, the five-day volume-weighted average price of the common shares of Emerald on the TSX Venture Exchange (the "TSXV"), discounted 10%, calculated as of April 30, 2019. The agreement to receive shares in lieu of cash was previously announced by the Company on May 1, 2019.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics to Lead International Affairs Council on CBD and Hemp’s Dialog with FDA on CBD Product Policy as Part of the American Trade Association for Cannabis and Hemp

    OTCQX: EMHTF) has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its International Affairs Council on CBD and Hemp in ATACH’s engagement with the US Food & Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade. The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the US.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Appoints Chief Operating Officer

    VICTORIA, British Columbia, May 22, 2019 -- Emerald Health Therapeutics, Inc. ("Emerald") (TSXV:EMH; OTCQX:EMHTF) has appointed Sean Rathbone as Chief Operating Officer. Mr..

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics to Hold Conference Call on First Quarter 2019 Financial Results on May 31st

    OTCQX: EMHTF) will host its first quarter 2019 financial results conference call on Friday, May 31st, 2019 at 10:30 a.m. ET. The Company will report its financial results for the first quarter ended March 31, 2019, after the market close on Thursday, May 30th, 2019. Emerald Health Therapeutics, Inc. is a Canadian licensed producer of cannabis.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Announces Pure Sunfarms’ Receipt of Standard Processing License for Delta 3 Greenhouse Facility

    OTCQX: EMHTF) today announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, has received a Standard Processing License (the “Processing License”) from Health Canada for its 1.1 million square foot Delta 3 greenhouse facility. The Processing License permits Pure Sunfarms to extract and process cannabis at its Delta 3 facility, which will enable the development and manufacture of products derived from cannabis, including oils, other concentrates, and edibles. Pure Sunfarms will require an additional amendment to its sales license to sell cannabis oil, which it expects to be distributing to provincial/territorial distributors and private retailers by the fourth quarter of this year.

  • PR Newswire2 months ago

    Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Introduces Unique Premium CBD Oil SYNC 25 to British Columbia Recreational Marketplace

    VANCOUVER, British Columbia, May 17, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has shipped 6,000 40 ml units of its SYNC 25 CBD oil to the.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics to Participate in Cowen Toronto Cannabis Summit

    VANCOUVER, British Columbia, May 15, 2019 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) will participate in Cowen’s Toronto Cannabis Summit on May.

  • CNW Group2 months ago

    Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th

    Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th